Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Avikam Harel is active.

Publication


Featured researches published by Avikam Harel.


Biochemical Pharmacology | 2002

Sensitivity of HaCat keratinocytes to diabetogenic toxins.

Avikam Harel; Olga Bloch; Pnina Vardi; Konstantin Bloch

Metabolic, genetic and environmental factors very likely play an important role in the development of skin lesions in diabetes mellitus. While these lesions are involved in secondary diabetes complications, various diabetogenic genotoxic agents may induce direct skin damage. In the present study we examined the potential of known diabetogenic agents (streptozotocin (STZ) and alloxan (AL)), with different mechanisms of action, for induction of direct injury in an immortal human keratinocyte HaCat cell line. In contrast to STZ, which induces alkylation of DNA, a genotoxic effect of AL is achieved through reactive oxygen species. We found that HaCat cells are highly sensitive to STZ, but not to AL. At a concentration of 10mM STZ, cell viability decreased to 32 +/-13% of control (P<0.05), as compared to 82 +/-14% with 10mM of AL. Cells treated with 10 and 20mM STZ showed a significant increase in apoptosis (3.9- and 6.7-fold), but not in necrosis, compared to naive cells (P<0.05). In contrast to STZ, no increase in apoptotic and necrotic cell death was observed after AL treatment. Pretreatment with non-metabolizable 3-O-methyl glucose (3-OMG), which can blockade glucose transporter, or with poly(ADP-ribose) polymerase inhibitors (nicotinamide or 3-aminobenzamide), did not protect keratinocytes from STZ injury. Our results show that STZ, but not AL, is highly toxic to the HaCat cell line. Unlike insulin-producing cells, STZ-induced injury of immortal human keratinocyte HaCat cells is independent of the glucose transporters as well as of the activation of poly(ADP-ribose) polymerase.


Archive | 2006

Compositions and methods for treating hyperproliferative epidermal diseases

Avikam Harel; Zeev Even-Chen; Bloch Olga


Archive | 2003

Composition and methods for the treatment of skin disorders

Avikam Harel; Olga Bloch


Archive | 2006

Composition and Methods for Skin Care

Avikam Harel; Zeev Even-Chen; Olga Bloch


Archive | 2001

AGENTS, SUCH AS NICOTINAMIDE OR cADPR FOR THE TREATMENT OF SKIN DISORDERS

Avikam Harel; Olga Bloch


Archive | 2016

COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS

Avikam Harel; Olga Bloch


Archive | 2006

Compositions comprising calcipotriol and nicotinamide for treating hyperproliferative epidermal diseases

Avikam Harel; Zeev Even-Chen; Olga Bloch


Archive | 2006

Compositions et methodes pour traiter des maladies epidermiques hyperproliferatives

Zeev Even-Chen; Avikam Harel


Archive | 2006

Compositions and methods for the treatment of hyperproliferative epidermal diseases

Avikam Harel; Zeev Even-Chen


Archive | 2006

Zusammensetzungen und verfahren zur behandlung von hyperproliferativen epidermalen erkrankungen

Avikam Harel; Zeev Even-Chen

Collaboration


Dive into the Avikam Harel's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge